FY2025 EPS Estimates for ARTV Decreased by Cantor Fitzgerald

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for Artiva Biotherapeutics in a report released on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($3.04) per share for the year, down from their prior forecast of ($2.91). Cantor Fitzgerald has a “Overweight” rating and a $20.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share.

ARTV has been the topic of a number of other reports. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday, April 8th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, March 26th. Finally, Wedbush reiterated an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $2.05 on Wednesday. The business has a 50 day moving average of $3.08 and a 200 day moving average of $6.73. Artiva Biotherapeutics has a 1-year low of $1.78 and a 1-year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.15).

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC purchased a new stake in shares of Artiva Biotherapeutics during the third quarter valued at approximately $304,000. Franklin Resources Inc. bought a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $7,435,000. JPMorgan Chase & Co. bought a new stake in Artiva Biotherapeutics during the 3rd quarter valued at $166,000. China Universal Asset Management Co. Ltd. purchased a new stake in Artiva Biotherapeutics during the 4th quarter valued at $52,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Artiva Biotherapeutics by 8.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after acquiring an additional 3,233 shares during the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.